These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 6668067)

  • 1. The use of moxalactam in the treatment of serious infections due to multi-resistant organisms.
    Srinivasan S; Francke EL; Ortiz-Neu C; Prince AS; Neu HC
    Infection; 1983; 11(6):291-5. PubMed ID: 6668067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Moxalactam therapy of difficult infections in patients with serious underlying conditions.
    Mogabgab WJ; Bauman DC; LaCorte WF; Pollock B; Pauling B; Beville RB; Holmes BJ
    J Int Med Res; 1983; 11(5):269-78. PubMed ID: 6642067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Moxalactam therapy of serious pediatric infections.
    Reed MD; Aronoff SC; Blumer JL
    Drug Intell Clin Pharm; 1984 Sep; 18(9):723-6. PubMed ID: 6479022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A clinical study of moxalactam in the treatment of infections due to gram-negative bacilli.
    DeMaria A; McCabe WR
    Scand J Infect Dis; 1984; 16(1):83-97. PubMed ID: 6695159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Empiric therapy with moxalactam alone in patients with bacteremia.
    Wilson WR; Henry NK; Keys TF; Anhalt JP; Cockerill FR; Edson RS; Geraci JE; Hermans PE; Muller SM; Rosenblatt JE
    Mayo Clin Proc; 1984 May; 59(5):318-26. PubMed ID: 6727424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Moxalactam therapy of serious infections.
    Van der Auwera P; Clumeck N; Van Laethem Y; Vanhoof R; Butzler JP
    Infection; 1983; 11(4):212-8. PubMed ID: 6618677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical evaluation of moxalactam: evidence of decreased efficacy in gram-positive aerobic infections.
    Salzer W; Pegram PS; McCall CE
    Antimicrob Agents Chemother; 1983 Apr; 23(4):565-70. PubMed ID: 6222696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hemorrhagic tendency as a complication of Moxalactam therapy in bacterial meningitis.
    Chan-Lui WY; Stroebel AB; Yeung CY
    Brain Dev; 1983; 5(4):417-20. PubMed ID: 6638397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized prospective study comparing moxalactam and cefoxitin with or without tobramycin for the treatment of serious surgical infections.
    Tally FP; Kellum JM; Ho JL; O'Donnell TF; Barza M; Gorbach SL
    Antimicrob Agents Chemother; 1986 Feb; 29(2):244-9. PubMed ID: 3717931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Moxalactam therapy for bacterial infections.
    Winston DJ; Busuttil RW; Kurtz TO; Young LS
    Arch Intern Med; 1981 Nov; 141(12):1607-12. PubMed ID: 6458253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical evaluation of moxalactam.
    Livingston WK; Elliott AM; Dismukes WE; Avent CK; Cobbs CG
    Antimicrob Agents Chemother; 1981 Jul; 20(1):88-97. PubMed ID: 6456688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imipenem versus moxalactam in the treatment of serious infections.
    Eron LJ; Hixon DL; Park CH; Goldenberg RI; Poretz DM
    Antimicrob Agents Chemother; 1983 Dec; 24(6):841-6. PubMed ID: 6581755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and clinical evaluation of moxalactam.
    Tanphaichitra D; Srimuang S
    J Med Assoc Thai; 1986 Feb; 69(2):82-7. PubMed ID: 3711748
    [No Abstract]   [Full Text] [Related]  

  • 14. Ticarcillin plus clavulanic acid versus moxalactam therapy of osteomyelitis, septic arthritis, and skin and soft tissue infections.
    Siebert WT; Kopp PE
    Am J Med; 1985 Nov; 79(5B):141-5. PubMed ID: 4073082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Moxalactam (latamoxef). A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
    Carmine AA; Brogden RN; Heel RC; Romankiewicz JA; Speight TM; Avery GS
    Drugs; 1983 Oct; 26(4):279-333. PubMed ID: 6354685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Double-blind, prospective, multicenter trial comparing ceftazidime with moxalactam in the treatment of serious gram-negative infections.
    Joshi M; Anthony WC; Tenney JH; Drusano GL; Caplan ES; Standiford HC; Henson A; Warren JW
    Antimicrob Agents Chemother; 1986 Jul; 30(1):90-5. PubMed ID: 3530128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Moxalactam versus clindamycin plus tobramycin in the treatment of obstetric and gynecologic infections.
    Sweet RL; Ohm-Smith M; Landers DV; Robbie MO
    Am J Obstet Gynecol; 1985 Aug; 152(7 Pt 1):808-17. PubMed ID: 3895947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of neutropenic infection: a randomized trial comparing latamoxef (moxalactam) with cephradine plus tobramycin.
    Bezwoda WR; Derman DP; Perkins S; Cassel R
    J Antimicrob Chemother; 1985 Feb; 15(2):239-45. PubMed ID: 3884566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ticarcillin plus clavulanic acid versus moxalactam in the treatment of skin and soft tissue infections.
    Rao B; See RC; Chuah SK; Bansal MB; Lou MA; Thadepalli H
    Am J Med; 1985 Nov; 79(5B):126-9. PubMed ID: 4073078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Failure of moxalactam in the treatment of neonatal sepsis and meningitis from Salmonella typhimurium.
    Adler SP; Markowitz SM
    J Pediatr; 1983 Dec; 103(6):913-6. PubMed ID: 6358437
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.